BR112022013575A2 - Anticorpos conjugados com moléculas de ácido graxo e usos dos mesmos - Google Patents

Anticorpos conjugados com moléculas de ácido graxo e usos dos mesmos

Info

Publication number
BR112022013575A2
BR112022013575A2 BR112022013575A BR112022013575A BR112022013575A2 BR 112022013575 A2 BR112022013575 A2 BR 112022013575A2 BR 112022013575 A BR112022013575 A BR 112022013575A BR 112022013575 A BR112022013575 A BR 112022013575A BR 112022013575 A2 BR112022013575 A2 BR 112022013575A2
Authority
BR
Brazil
Prior art keywords
antibodies
fatty acid
acid molecules
conjugated antibodies
conjugated
Prior art date
Application number
BR112022013575A
Other languages
English (en)
Inventor
Chongyang Li Jack
Jia Haiqun
Zou Hui
Wang Minghan
Original Assignee
Phanes Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phanes Therapeutics Inc filed Critical Phanes Therapeutics Inc
Publication of BR112022013575A2 publication Critical patent/BR112022013575A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Abstract

ANTICORPOS CONJUGADOS COM MOLÉCULAS DE ÁCIDO GRAXO E USOS DOS MESMOS. A presente invenção refere-se a anticorpos monoclonais (mAbs) ou anticorpos biespecíficos (bsAbs) ou anticorpos multiespecíficos compreendendo uma molécula de ácido graxo (FA) conjugada com ou próximo ao domínio de ligação ao antígeno. Também são descritos ácidos nucleicos que codificam os anticorpos, composições que compreendem os anticorpos, e métodos para produzir os anticorpos e usar os anticorpos para tratar ou prevenir doenças, como câncer e/ou complicações associadas.
BR112022013575A 2020-02-27 2021-02-25 Anticorpos conjugados com moléculas de ácido graxo e usos dos mesmos BR112022013575A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982476P 2020-02-27 2020-02-27
PCT/US2021/019583 WO2021173783A1 (en) 2020-02-27 2021-02-25 Antibodies conjugated with fatty acid molecules and uses thereof

Publications (1)

Publication Number Publication Date
BR112022013575A2 true BR112022013575A2 (pt) 2022-09-13

Family

ID=77490164

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013575A BR112022013575A2 (pt) 2020-02-27 2021-02-25 Anticorpos conjugados com moléculas de ácido graxo e usos dos mesmos

Country Status (11)

Country Link
US (1) US20230089926A1 (pt)
EP (1) EP4110398A1 (pt)
JP (1) JP2023515196A (pt)
KR (1) KR20220145854A (pt)
CN (1) CN115279412A (pt)
AU (1) AU2021226336A1 (pt)
BR (1) BR112022013575A2 (pt)
CA (1) CA3164646A1 (pt)
IL (1) IL295413A (pt)
MX (1) MX2022010657A (pt)
WO (1) WO2021173783A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060099208A1 (en) * 2004-11-08 2006-05-11 Undurti Das N Method of potentiating the therapeutic action of monoclonal and polyclonal antibodies
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2803188A1 (en) * 2010-07-09 2012-01-12 Antonello Pessi Lipid-conjugated antibodies
EP3892294A1 (en) * 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions

Also Published As

Publication number Publication date
WO2021173783A1 (en) 2021-09-02
IL295413A (en) 2022-10-01
AU2021226336A1 (en) 2022-08-11
CN115279412A (zh) 2022-11-01
EP4110398A1 (en) 2023-01-04
US20230089926A1 (en) 2023-03-23
KR20220145854A (ko) 2022-10-31
CA3164646A1 (en) 2021-09-02
JP2023515196A (ja) 2023-04-12
MX2022010657A (es) 2022-09-23

Similar Documents

Publication Publication Date Title
CL2021002645A1 (es) Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos. (divisional de solicitud 201900726)
CO2019003923A2 (es) Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos
ECSP20075198A (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos
PE20210321A1 (es) Anticuerpos biespecificos contra dll3-cd3
BR112017027582A2 (pt) método para inibição do crescimento de uma célula tumoral ou promoção da eliminação de uma célula tumoral, e, composição farmacêutica.
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
ECSP22019193A (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer antecedentes de la invención
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
BR112022019531A2 (pt) Molécula biespecífica de ligação ao antígeno, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos para produzir uma molécula biespecífica de ligação ao antígeno e para tratar um indivíduo com câncer, composição farmacêutica e uso da molécula biespecífica
BR112015023086A2 (pt) anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
BR112018072716A2 (pt) molécula de ácido nucleico, composição, e, métodos para tratar uma doença e para prevenir ou tratar a formação de um biofilme.
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
BR112022000628A2 (pt) Anticorpos anti-tigit e aplicação dos mesmos
EA201991845A1 (ru) Фармацевтические комбинации, содержащие антитело к ly75
BR112022013575A2 (pt) Anticorpos conjugados com moléculas de ácido graxo e usos dos mesmos
CO2022017445A2 (es) Proteínas multiespecíficas
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
EA201992715A1 (ru) Способ и молекулы
UY39699A (es) Anticuerpos anti-tau y usos de estos
UY38520A (es) Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos
EA202092122A1 (ru) Антитела против tip-1 и их применения